Merck & Co., Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a third-quarter net income of $5.065 billion alongside a nine-month net loss attributable to the company of $510 million.

Key Highlights

  • Q3 2026 sales: $18,085 million, up from $17,276 million in Q3 2025, according to the filing.
  • Nine-month net loss: Net loss attributable to Merck & Co., Inc. was $510 million for the nine months ended September 30, 2026, compared to net income of $15,291 million in the same period of 2025.
  • Q3 diluted EPS: $2.04 per share for the three months ended September 30, 2026, versus $2.32 in Q3 2025.
  • Nine-month R&D expense: Research and development costs totaled $26,871 million for the nine months ended September 30, 2026, versus $11,903 million in the prior-year period, driven in part by $13,811 million in charges for research and development asset acquisitions.
  • Three acquisitions completed: The company disclosed acquisitions of Cidara Therapeutics, Inc. ($8,779 million net of cash), Terns Pharmaceuticals, Inc. ($5,842 million net of cash), and TARGAN ($630 million net of cash) during the nine-month period.
  • Long-term debt increased: Long-term debt stood at $49,689 million as of September 30, 2026, up from $46,750 million at December 31, 2025.
  • Shares outstanding: 2,465,245,688 common shares were outstanding as of October 31, 2026.

Merck Reports Q3 2026 Results Amid Elevated R&D and Acquisition Spending

According to the filing, Merck & Co., Inc. (NYSE:MRK) reported sales of $18,085 million for the three months ended September 30, 2026, compared to $17,276 million for the same quarter in 2025. Net income attributable to the company in the third quarter was $5,065 million, or $2.04 per diluted share, versus $5,785 million, or $2.32 per diluted share, in Q3 2025. For the nine months ended September 30, 2026, the company reported a net loss attributable to Merck of $510 million, or $(0.21) per basic and diluted share, a reversal from net income of $15,291 million, or $6.08 per diluted share, in the prior-year nine-month period.

The filing indicates that nine-month research and development expenses reached $26,871 million, more than double the $11,903 million recorded in the same period of 2025. The company disclosed that this increase included $13,811 million in "charges for research and development asset acquisitions," reflected as a non-cash or one-time item in the cash flow statement's operating activities reconciliation. Total costs and expenses for the nine months were $49,636 million, compared to $30,964 million in 2025, contributing to income before taxes of $1,342 million versus $17,647 million in the prior-year period.

On the balance sheet, total assets were $132,773 million as of September 30, 2026, down from $136,866 million at December 31, 2025. Cash and cash equivalents declined to $9,550 million from $14,565 million. The company reported net cash provided by operating activities of $15,846 million for the nine months, while net cash used in investing activities was $17,131 million, reflecting the three acquisitions. Restructuring costs for the nine months were $530 million, compared to $676 million in the prior-year period. Dividends paid to stockholders totaled $6,348 million for the nine months ended September 30, 2026.

What Was Disclosed

Merck filed its quarterly Form 10-Q covering the period ended September 30, 2026, disclosing a nine-month net loss of $510 million attributable to the company, driven by sharply higher R&D costs and acquisition-related charges, alongside three completed acquisitions totaling approximately $15.25 billion.